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                                         Domperidone (DOM) is a dopamine- receptor (D2) 
antagonist, widely used in the treatment of motion-sickness. The pharmacokinetic parameters 
of DOM make it a suitable candidate for development of Solid Lipid Nanoparticle (SLN) 
and Nanostructured Lipide Carrier (NLC). The purpose of the present investigation was to 
prepare and evaluate DOM loaded solid lipid nanoparticles (DOM-SLN) and DOM loaded 
nanostructured lipid carriers (DOM-NLC).
         DOM loaded SLN and NLC were prepared by hot homogenization followed by 
ultrasonication technique, using trimyristin as solid lipid, cetyl recinoleate as liquid lipid 
and a mixture of soy phosphatidylcholine (99%) and tween 80 as surfactant. SLN and NLC 
were characterized for particle size, polydispersity index (PDI), zeta potential and entrapment 
                                                                                                
                                                                                                     
were investigated. DSC analysis was performed to characterize the state of drug and lipid 
                                                                                            
microscopy (TEM). SLN and NLC formulations were subjected to stability study over a 
period of 40 days. 
                                                                                               
(SLN1) and NLC were found to be 30.45 nm, 0.156, 12.40 mV, 87.84 % and 32.23 nm, 0.160, 
10.47 mV, 90.49 % respectively. DSC studies revealed that DOM was in an amorphous state 
                                                                                        
was determined by TEM revealed fairly spherical shape of nanoparticles. In vitro release studies 
demonstrated that both the SLN and NLC formulations possessed a controlled release over 
a period of 24 hrs. SLN and NLC formulations were subjected to stability over a period of 
                                                                                             
                                                                             
            Fairly spherical shaped, stable and controlled release DOM-SLN and DOM-NLC 
could be prepared by hot homogenization followed by ultrasonication technique.
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Nanoparticles can be prepared using different kinds of 
materials, such as, biodegradable and biocompatible 
polymers,  phospholipids,  surfactants  and  lipids       
(1, 2). Several advantages of nanoparticles prepared 
from lipid materials including biocompatibility, drug 
                                                   
production have been demonstrated (3). SLN have 
more advantages for drug delivery system, because 
of a good tolerability due to the use of physiological 
lipids (4), larger scale production and also a 
targeting effect on brain (5). However, depending 
on the drug, some potential problems can occur, 
                                                    
total drug load. To overcome the limitations of 
SLN, nanostructured lipid carriers (NLC) have been 
developed (2).
SLN and NLC are colloidal lipid systems, which 
have been proposed for several administration 
routes, such as parenteral (6), oral (7) and topical 
                                                     
many substances. SLN consist of pure solid lipids 
and NLC contain a certain percentage of additional 
liquid lipids leading to imperfections in the crystal 
lattice. These nanoparticles are produced by one 
of the following techniques, namely, high pressure 
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homogenization (9), microemulsion template (10), 
                                                     
solvent diffusion (12), reverse micelle-double 
emulsion (13), homogenization followed by 
ultrasonication (8), solvent injection (14), and a very 
recently introduced membrane contractor techniques 
(15).
Domperidone is a dopamine-receptor (D2) anta-
gonist, widely used in the treatment of motion 
sickness. It is poorly water soluble (log p, 3.1) and 
has low absorbability after oral administration, 
                                                   
leading to poor bioavailability of 15% (16, 17). In 
addition, it is supplied at low dose (10 mg) and has 
low molecular weight (425.9), require long term 
treatment and repetitive dosing which make this 
drug an interesting candidate for development of 
SLN and NLC. 
The objective of the present research was to study 
the preparation of SLN and NLC loaded DOM 
by homogenization followed by ultrasonication 
technique and to study the effects of composition of 
lipid materials and surfactant mixture on the particle 
                                                    
in vitro drug release behavior in detail. 
                    
        
Domperidone (Torrent pharmaceuticals, Ahmadabad, 
                                                       
                                                  
                                                   
                                                  
Tween 80 and dialysis membrane-70 (Hi-media, 
                                                    
cutoff 20,000) (Sartorius, Goettingen, Germany) 
were used in this study. All other chemicals were of 
analytical reagent grade. 
                                             
Domperidone, trimyristin, and soy phosphatidyl-
choline 99% were dissolved in 10 ml mixture of 
chloroform and methanol (1:1). Organic solvents 
were completely removed using a rotaevaporator 
(Laborota 4000, Heidolph, Germany). Drug-
embedded lipid layer was melted by heating at 5°C 
above melting point of the lipid. An aqueous phase 
was prepared by dissolving polysorbate 80 in double 
                                                   
preparation) and heated to the same temperature of 
oil phase. Hot aqueous phase was added to the oil 
phase, and homogenization was carried out at 12,000 
rpm using a Diax 900 homogenizer (Heidolph, 
Germany) for 3 min. Coarse hot oil in water 
emulsion was ultrasonicated (12T-probe) using a 
sonoplus ultrahomogenizer (Bandelin, Germany) for 
20 min. DOM-SLN were obtained by allowing hot 
nanoemulsion to cool to room temperature. 
Domperidone loaded NLC (DOM-NLC) was 
prepared in exactly the same manner as the SLN 
dispersions, but replacing 30% of the solid lipid by 
                                                       
of the investigated SLN and NLC dispersions are 
shown in table 1.
                                                   
           
The size and zeta potential of SLN were measured 
by photon correlation spectroscopy using a 
Zetasizer 3000 HSA (Malvern, UK). Samples were 
diluted appropriately with the aqueous phase of the 
formulation to get optimum kilo counts per second 
(Kcps) of 50-200 for measurements, and the pH of 
diluted samples ranged from 6.9 to 7.2. Zeta potential 
measurements were carried out at 25°C, and the 
                                            
                                     
                                              
by measurement of the concentration of free drug 
(unentrapped) in aqueous medium using centrisart 
tubes (Sartorius, Germany) (18). The entrapment 
                                                   
 
                      
analyzed weight of drug 
in SLN
  100
theoretical weight of drug 
loaded in SLN 
                                
HPLC determination of DOM was performed 
using Shimadzu LC 20AT solvent delivery pump 
equipped with a 20 μl loop and rheodyne sample 
injector and UV-Visible detector operating at 284 
nm. Samples were chromatographed on a stainless 
steel C18 reverse phase column (250 x 4.25 mm) 
                                               
column). Elution was conducted with a mobile 
phase of acetonitrile: double distilled water: 
                                                     
of 1 ml.min-1and the entire analysis was carried 
out at room temperature. A calibration curve was 
plotted for DOM in the concentration range of 0.5-
10 μg.ml-1. A good linear relationship was observed 
between the concentration of DOM and the peak 
                                            2 = 
0.999). The required studies were carried out to 
estimate the precision and accuracy of the HPLC 
method (17).
                      
In vitro release studies were performed using 
dialysis membrane (Hi-media, Mumbai, India) 
having pore size of 2.4 nm and molecular weight 
cutoff between 12,000-14,000 Dalton. Membrane 
was soaked in double distilled water for 12 hrs Thatipamula et al / DARU 2011 19 (1) 23-32 25
before mounting in a Franz diffusion cell. A volume 
of 2 ml of DOM loaded SLN/NLC was placed in the 
donor compartment and the receptor compartment 
                                               
buffer of pH 6.8 and mixture at 37±0.5°C was 
stirred at 800 rpm. An aliquot of 1ml of the sample 
was withdrawn from receiver compartment at pre-
determined time intervals and replenished with fresh 
medium. Samples were analyzed by HPLC. Data 
                                                     
                                                   
of DOM release from SLN and NLC. The Kinetic 
                                                  
used in this study.
                                        
Thermal characteristics of the drug, trimyristin (TM), 
physical mixture (PM), lyophilized DOM-SLN and 
lyophilized DOM-NLC were studied by Mettler-
                                                  
                                                         
of 50 ml min-1. Samples were analyzed in crimped 
aluminum pans and heated at 30 - 250°C at a linear 
heating rate of 10°C min-1. The sample size was 3-5 
mg for each measurement.
                                         
Images were recorded using Transmission Electron 
Microscope (Hitachi, Japan, Model H 7500 ID) with 
                                               
NLC was diluted appropriately with 0.1M phosphate 
buffer and centrifuged at 4000 rpm for 5 min. Few 
drops of the diluted emulsion was placed on grid and 
stained with 2% uranyl acetate, and then the image 
was captured.
                 
DOM loaded SLN and NLC were stored at room  and 
refrigerator temperature for 40 days. At different time 
intervals of the days of 1, 20 and 40, the average size, 
                                                  
determined. Samples were estimated in triplicates. 
Statistical analysis of the data was performed using 
the Student’s  -test.  A probability,  , of less than 0.05 
                                                 
                       
                                     
Homogenization followed by ultrasonication is 
a reliable, simple and reproducible method for 
preparation of SLN and NLC (18). It is known 
that employment of two surfactants of lipophilic 
and hydrophilic nature yields a better stabilization 
of the disperse system. The solvent mixture of 
chloroform and methanol (1:1) was found to be 
effective in homogenously dispersing of the drug in 
the lipid phase. Homogenization of the lipid phase 
                                                  
to produce a coarse emulsion with average particle 
size between 2.52 and 2.83 μm. Further increase in 
                                                
decrease in the particle size. Thus a homogenization 
time of 3 min was selected for all formulations and 
further reduction of size was preceded with sonication. 
Sonicating the coarse emulsion for 20 min resulted in 
particle size between 30 and 38 nm with narrow size 
distribution. In order to optimize the lipid to drug 
ratio, two different amounts of trimyristin (250 and 
                                               
mg) and soy phosphatidylcholine 99% (100 mg). 
                                                       
             
In all formulations, the particle sizes ranged from 
30.4±6.12 to 38.1±5.12 nm (Table 2). Increase in 
the concentration of surfactant in SLN formulations 
could reduce the interfacial tension between lipid 
matrix and dispersion medium (aqueous phase), 
consequently favor the formation of SLN with 
smaller particle size. Tween 80 also  maintain the 
stability of SLN (18). To obtain stable and smaller 
SLN, tween 80 concentrations were varied from 
0.75 to 1.5 % (150 to 300 mg). From the results it is 
evident that the concentration of 1.5% was effective 
in producing smaller particle size. Further increase 
in Tween 80 concentration to 2% had no effect in 
reduction of the particle size. These results clearly 
suggest that an optimum concentration of 1.5% 
                                                  
nanoparticles effectively and prevent agglomeration 
during the homogenization process. 
Zeta potential is a key factor for evaluation of the 
stability of colloidal dispersion. It was currently 
admitted that zeta potentials above 30 mV were 
required for full electrostatic stabilization. The 
values of zeta potential of DOM loaded SLN and 
NLC ranged from 5.82±1.22 to 12.4±4.72 (Table 
                                                    
However, many experiments demonstrated that not 
only electrostatic repulsion dominated the stability 
of nanoparticles but the use of steric stabilizer 
also favored the formation of stable nanoparticle 
dispersion. High surfactant mixture can easily 
compensate missing electrostatic repulsion to 
stabilize the dispersion for long time. Tween 80 
provides a steric stability for maintaining the stability 
of SLN and NLC.
                    
                                                 
are shown in table 2. Among the SLN formulations 
                                                  
observed with formulation of SLN1, whereas 
formulation SLN4 showed lowest entrapment 
                                                    
decreased there was a decline in entrapment 
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(90.49±7.01%). In general, drug solubility is higher 
in liquid lipid than in solid lipid, which increases the 
                                                   
lipids to solid lipids leads to reduced crystallinity 
and increased imperfections in the crystal lattice 
which leaves enough space to accommodate drug 
molecules, thus, leading to improved drug loading 
                                       
                                                    
                 
The effect of surfactant composition on the size, zeta 
potential and PDI of SLN and NLC are presented 
                                                
NLC is an important factor for determination of 
the physicochemical characteristics due to the 
surface active properties. The zeta potential of SLN 
formulations (SLN1 to SLN8) was decreased by 
decrease in the total amount of surfactant mixture 
(soy phosphatidylcholine & tween 80) from 400 to 
250 mg. As the amount of surfactant mixture was 
increased, the particle size was decreased. The 
                                                  
size and the stability of the formulation. The 
                                               
the surface of the nanoparticles and combination 
of hydrophilic and lipophilic surfactants were used 
in the formulation to improve the stability of the 
formulation.
                      
The in vitro                                    
SLNs with different formulations and DOM-
loaded NLC are shown in             . In order 
to evaluate the controlled release potential of the 
investigated formulations, the release of DOM 
from the lipid particles was investigated for 24 
hrs. Maximum amount of drug release was found 
from the formulations SLN 5 to SLN 8 compared 
to the formulations SLN 1 to 4 in 0.1N HCl and 
                                                
low concentration of lipid in the formulations. 
Formulations SLN 4 and 8 showed maximum drug 
           
            
SLN1 SLN2 SLN3 SLN4 SLN5 SLN6 SLN7         
DOM (mg) 10 10 10 10 10 10 10 10 10
TM (mg)a 300 300 300 300 250 250 250 250 210
SP 99% (mg)b 100 100 100 100 100 100 100 100 -
CR (mg)c -------- 9 0
SS (mL)d 10 10 10 10 10 10 10 10 10
Tween 80 (mg)e 300 250 200 150 300 250 200 150 300
aTM: trimyristin
bSP 99% : Soy Phosphatidyl choline
cCR: Cetyl resinoleate
d SS: solvent system (1:1 ratio of chloroform and methanol)
e Tween 80: used in 20 ml of double distilled water
         Composition of DOM-SLN and DOM-NLC formulations.
            a                                           bEE %
SLN 1 0.15±0.091 30.4±6.12 12.4±4.72 87.8±7.07
SLN 2 0.14±0.012 31.3±5.55 10.4±4.68 84.1±6.33
SLN 3 0.20±0.008 34.8±9.91 7.26±3.11 83.1±4.99
SLN 4 0.18±0.021 33.4±4.89 6.27±2.58 81.7±8.22
SLN 5 0.19±0.011 33.6±2.33 7.76±3.61 85.1±5.48
SLN 6 0.22±0.016 35.6±6.47 6.44±2.48 84.8±6.78
SLN 7 0.21±0.014 38.1±5.12 6.94±2.15 82.9±7.66
SLN 8 0.19±0.025 37.8±6.66 5.82±1.22 80.9±8.71
NLC 0.16±0.015 32.2±6.61 10.4±3.16 90.5±7.01
aPDI: polydispersity index
b                         
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release in 12 hrs, whereas for SLN 3 and 7 were 18 
hrs. As the surfactant concentration decreased from 
1.5% to 0.75% there was a decrease in controlled 
release properties of the SLN formulations. In the 
NLC formulation 30% of the solid lipid was replaced 
by liquid lipid. Due to the addition of liquid lipid in 
the NLC formulation there was an increase in the 
amount of drug release in comparison to the SLN 
1, since the liquid lipid adheres to the lipid matrix 
and decreases the diffusion path length of the lipid 
matrix. The data for drug release of most of the SLN 
                                               
square root release kinetics (r2 values ranging from 
0.92 to 0.99). This indicates that the test product 
follows matrix diffusion based release kinetics.
            
DSC thermograms of DOM, trimyristin, physical 
mixture of drug and lipid, SLN and NLC are shown 
                                              
was in an amorphous state and triglycerides are in 
                                             
endotherm of the drug was completely absent 
in the thermograms of DOM loaded SLN and 
NLC, which indicates that DOM was completely 
solubilized inside the lipid matrix of the SLN and 
NLC. Incorporation of DOM inside the lipid matrix 
results in an increase in the number of defects in 
the lipid crystal lattice, and hence causes a decrease 
                                                  
formulations. Bulk trimyristin showed a sharp 
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          Effect of surfactant composition on the size, zeta potential and PDI of SLN and NLC formulations.
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endothermic event, around 58.68°C (minimum) 
with an extrapolated onset of the melting peak at 
53.28°C. When the trimyristin was formulated 
as nanoparticles, the endothermic happened at 
a slightly lower temperature and in the form of 
beta prime polymorph. These differences are 
generally ascribed to the nanometric size of the 
                                                   
(20). A certain effect due to the surfactant should 
also be considered. The addition of oil (i.e., cetyl 
resinoleate) into the matrix provoked an additional 
shift of the melting point to lower temperatures in 
NLC.
                                                  
     
The result of TEM imaging of DOM loaded SLN 
and NLC, which are shown in          indicate that 
the particles had nanometer-size spherical shapes 
and no drug crystal (irregular crystallization with the 
vast majority of needle or rod crystal in the length 
range from 10 micron to a few dozen microns) was 
visible. The average particle size of optimized DOM 
loaded SLN and DOM loaded NLC were found to be 
30.45 nm and 32.23 nm respectively.
               
All formulations were stored in amber colored 
bottles at room and refrigerator temperature. As 
SLN 3, 4, 7 and 8 formulations are not stable, 
only formulations SLN 1, 2, 5, 6 and NLC were 
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analyzed for particle size, zeta potential and PDI 
after stored at room and refrigerator temperature 
for the days of 1, 20 and 40. SLN 1, 2, 5, 6 and 
                                                    
the different time intervals (day 1, 20 and 40) after 
stored at room temperature. The effect of duration 
of storage condition on particle size, zeta potential 
and PDI of SLNs and NLC are shown in table 3 
                                                  
                                                      
and PDI between SLN and NLC on the day of 
preparation but as the duration of storage increased 
the NLC formulation found to be more stable than 
SLN. The good stability might derive from the slow 
transition of lipid in nanoformulations and the steric 
effect of tween 80. These results clearly suggest Thatipamula et al / DARU 2011 19 (1) 23-32 29
 
           DSC thermograms of DOM  (A) ,trimyristin (B), physical mixture of DOM and TM (C), and lyophilized DOM-NLC (D).
           DSC thermograms of DOM (A), trimyristin (B), physical mixture of DOM and TM (C), and lyophilized DOM-SLN (D).  
that an optimum tween 80 concentration of 1.5% 
                                                    
effectively and prevent agglomeration during the 
homogenization process.
During long-term storage, triglycerides undergo 
degradation to fatty acids and mono- and 
diglycerides, which could compete with formulation 
surfactants for positioning on the surface. Fatty acids 
and monoglycerides can form mixed micelles that 
might enhance partitioning of hydrophobic drug out 
of the nanoparticle. Therefore, the concentration 
of excipients and possible degradation of products 
need to be determined to understand the stability of 
nanoparticle (21). The effect of duration of storage 
condition at room temperature on entrapment 
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          Transmission electron micrograph of (A) DOM loaded SLN and (B) DOM loaded NLC.
A B
          
This study indicates that both SLN and NLC are 
potential carriers systems for DOM. The entrapment 
                                                
the concentration of lipid and surfactant mixture 
employed. NLC showed higher entrapment 
                                                      
with these results NLC also show a faster release 
                                                  
concentration. The release rate decreases for SLN 
with a higher lipid concentration, which is explained 
by the physical morphology of the lipid particles. 
Stability studies revealed that after 40 days of storage 
at different temperatures the mean diameters of NLC 
remain practically the same, which emphasizes 
the physical stability of lipid particles. These data 
collectively support that SLN and NLC are the 
promising delivery systems for poorly water soluble 
drugs, such as domperidone.
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Room temperature
Day 1
SLN1 30.45 ± 2.4 12.43±3.1 0.156±0.043
SLN2 31.37 ± 5.3 7.26±2.2 0.148±0.088
Day 20
SLN1 36.47 ± 2.5 8.14±2.3 0.215±0.056
SLN2 39.43 ± 3.8 5.31±4.1 0.213±0.066
Day 40
SLN1 38.37 ± 6.2 3.64±2.2 0.303±0.073
SLN2 41.29 ± 8.4 3.31±2.1 0.377±0.028
Refrigerator temperature
Day 1
SLN1 30.45±2.6 12.43±4.6 0.156±0.097
SLN2 34.88±6.6 7.26±4.3 0.201±0.066
Day 20
SLN1 41.08±4.9 6.56±2.4 0.268±0.058
SLN2 46.59±5.5 5.74±2.2 0.307±0.043
Day 40
SLN1 56.17±7.7 4.95±1.1 0.325±0.078
SLN2 58.25±7.5 3.26±2.4 0.322±0.054
Room temperature
Day 1
SLN5 33.61±4.8 10.43±5.4 0.189±0.066
SLN6 35.66±3.6 6.27±3.6 0.222±0.073
Day 20
SLN5 34.16±4.5 7.59±4.2 0.225±0.044
SLN6 38.51±6.3 5.23±2.4 0.401±0.057
 Day 40
SLN5 36.54±7.9 5.05±1.4 0.315±0.085
SLN6 39.96±8.8 1.61±1.1 0.420±0.077
Refrigerator temperature
Day 1
SLN5 31.37±3.4 10.43±5.8 0.148±0.089
SLN6 33.45±5.3 6.27±3.4 0.185±0.099
Day 20
SLN5 40.11±4.4 7.11±4.3 0.239±0.048
SLN6 42.89±2.8 5.88±4.1 0.260±0.088
Day 40
SLN5 53.51±8.8 5.33±2.4 0.44±0.092
SLN6 53.64±6.9 4.11±2.8 0.419±0.055
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